Swiss Biotech Day 2023 is only a couple weeks away! Medicilon is excited to attend and exhibit at the conference. Our VP of UK and Europe Business Development Ms. Nadine Su Our EVP and Head of IDSU, Dr. Xuedong Dai are invited to give a presentation to introduce Medicilon fully integrated drug discovery platform and focus on the topic of “The Application of Late-stage Modification in Drug Design”. Our Business Development team will be exhibiting at the conference. We are happy to meet you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs. We look forward to seeing you soon!
Date: April 24-25, 2023
Location: Congress Center Basel, Switzerland
Medicilon Booth: #57
The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed date in the community’s calendar. In 2022, the conference highlighted the impressive growth of the Swiss biotech industry and presented an exciting program with ideal networking opportunities for over 1,100 participants from across the globe.
In 2023, the Swiss Biotech Day will again offer high-level experts from the life sciences industry the space and the time (one and a half days) to network, discuss and discover trends in R&D, manufacturing, data management, artificial intelligence and innovative financing. In addition, international biotech delegations can visit the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments, public-private partnerships, research and development collaborations and exchange of talent.
What to expect
❖ Meet over 1,000 senior experts from the life science industry
❖ Swiss Biotech Success Stories awards
❖ Innovative biotech start-ups and medium-sized biotech companies
❖ Thematically-focused panel discussions
❖ Swiss Biotech Report 2023
❖ General assembly of the Swiss Biotech Association
Speakers
Dr. Xuedong Dai
Executive VP and Head of IDSU (International Discovery Service Unit) at Medicilon,obtained his Ph.D. in organic chemistry at MIT. He is a senior-level expertwith over 20 years of experience focusing on small molecule drug discovery and development in CNS, infectious disease, and oncology therapy areas. He has deep understanding and practical knowledge of drug discovery process, including leadidentification, optimization, and development of high quality clinical candidate molecules. Prior to Medicilon, Dr. Dai worked at Janssen, HD Biosciences, GSK, and Xenoportwith a demonstrated successful track record of program leadership and made significant contributions to medicinal chemistry programs that led to the marketed drug Horizant®/Regnite® and several other clinical candidates (JNJ-75276617, arbaclofen placarbil, XP21279, and XP23829).
Medicilon Chemistry Research Services
With the rapid development of the global pharmaceutical market and the division of labor in the pharmaceutical industry, the chain is becoming more and more refined, making specialized outsourcing in the pharmaceutical industry an important strategic choice for pharmaceutical companies. In the early stages of new drug development, FTE (Full-time equivalent) is often used by drug discovery companies to synthesize the required structural fragments and/or potential candidate compounds to accelerate the drug screening process.Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and customers can cooperate with us through the FFS (Fee for Service) or FTE (Full-time Equivalent Service) models.
Full-Time Equivalent (FTE)
Medicilon has a dedicated R&D and project management team. According to customer requirements, it can configure different proportions of R&D staff with different levels of Ph.D., M.S., or B.S. degrees to form a joint R&D team with customers to quickly and efficiently solve the technical problems of their R&D projects, and to provide regular project progress reports and project communication meetings. Moreover, Medicilon can quickly adapt to the client's needs and provide efficient output to ensure the smooth progress of the project. This partnership model is ideal for innovative drug development projects. The Medicilon Chemical FTE team can serve clients at different stages of drug development, including generation and optimization of lead compounds, identification, and optimization of lead compounds, synthesis scale-up, and chemical process studies. This collaboration model allows for flexible adjustment of R&D staffing, experimental protocols, and project priorities based on client and project needs. The research department will communicate with the customer when problems are encountered in the R&D process and propose solutions to solve them. In addition, the FTE team can not only synthesize according to the synthesis line designed by the customer but also design the synthesis line according to the customer's concept. Flexible adjustment based on project requirements makes project progress clear and controllable, and provides exclusive synthesis circuit design and problem solving, all of which reflect the service advantages of the Medicilon FTE team.
Fee For Service (FFS)
FFS custom synthesis is one of Medicilon's services. Medicilon has an experienced R&D team of Ph.D., M.S., and B.S. degree researchers who constitute a golden mix and will utilize their extensive biopharmaceutical and medicinal chemistry experience to complete a variety of different custom synthesis projects including the synthesis of biologically active molecular target compounds, and other drug-like intermediates regularly. The custom synthesis will be developed exactly to the customer's requirements for the compound, either in small (typic milligrams to 100 grams) or medium to large (typically 100 grams to kilograms) quantities. These drug-like substances include drug reference compounds, lead compounds and their derivatives, combinatorial chemical templates, and other drug-like compounds with or without references. We can deliver custom synthesis products in a timely and efficient manner. The fees charged for the FFS model depend on the type of specific experiment, the method and the number of compounds to be tested, etc.
Overview of Medicilon R&D technology platforms
PROTACs offer a fast and reversible chemical knock-down approach to control protein function in the cell. The impact of the PROTAC platform has changed the landscape of drug discovery and development. Medicilon’s PROTAC drug discovery technology platform covers many of the popular target protein ligands. We have established an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize highly active PROTAC bispecific small molecules, which have the potential to significantly facilitate the drug development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages. Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 3 PROTAC drugs by NMPA and/or FDA and has more than 20 PROTAC projects under development.
Medicilon has:
• Know-how: > 6 years PROTACs experience
• Comprehensiveness: > 20 ongoing projects
• Talent: > 300 dedicated well-trained chemists
• Team: > 300 dedicated well-trained chemists
• Building Block: > 300 advanced linkers Available
• Scaffold: > 150 E3 ligands available including Cereblon, VHL, MDM2, IAP, etc.
Medicilon started ADC non-clinical research in 2014. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 13 ADC drugs by NMPA and/or FDA and has more than 10 ADC projects under development. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins.
Featured Platform-Antibody
With the development of antibody technology, antibody now presents a good development prospect. While major companies are deploying antibody product research and development, they also pay great attention to what needs to be paid attention to and considered in the biological analysis of antibody. Regulations and technical points. The Pharmaceutical Analysis Department of Medicilon Biotechnology is committed to tailoring Case by Case biological analysis methods for customers. As of the end of 2022, Medicilon has successfully assisted in the clinical approval of 17 monoclonal antibody drugs and 7 bispecific antibody drugs by NMPA, FDA, and TGA.
Share：
Online registrationRelevant
news
marketing@medicilon.com
